Citations

Clear

1011 citation(s) found for "Barry, WT".

Surprising Course of a Pregnant Patient With Mosaic Turner Syndrome
Majdalany, David , Lee, Hong Seok , Barry, Timothy , Singh, Katherine , Chapa, Jeff , Pettersson, Gösta , Majdalany, David S , Lee, Hong , Pettersson, Gosta B

Mayo Clinic

Korean Circulation Journal | June 11, 2024 | Volume: 54 | Issue: 7 | Pages: 425

10.4070/kcj.2024.0095 | PMID 38956942 Get It

Circulating Beta-Hydroxybutyrate Levels in Advanced Heart Failure with Reduced Ejection Fraction: Determinants and Prognostic Impact
Monzo, Luca , Kovar, Jan, Beneš, Jan , Kotrč, Martin , Kroupova, Katerina, Jabor, A , Franeková, Janka , Kovar, Jan, Borlaug, Barry A. , Melenovský, Vojtěch

Mayo Clinic

European Journal of Heart Failure | June 10, 2024 | Volume: 26 | Issue: 9 | Pages: 1931-1940

10.1002/ejhf.3324 | PMID 38853653 Get It

Abstract Aims Patients with heart failure (HF) display metabolic alterations, including heightened ketogenesis, resulting in increased beta-hydroxybutyrate (β-OHB) formation. We aimed to investigate the determinants and prognostic impact of circulating β-OHB levels in patients with advanced HF and reduced ejection fraction (HFrEF). Methods and results A total of 867 patients with advanced HFrEF (age 57 ± 11 years, 83% male, 45% diabetic, 60% New York Heart Association class III), underwent clinical and echocardiographic examination, circulating metabolite assessment, and right heart catheterization (n = 383). The median β-OHB level was 64 (interquartile range [IQR] 33–161) μmol/L (normal 0–74 μmol/L). β-OHB levels correlated with increased markers of lipolysis (free fatty acids [FFA]), higher natriuretic peptides, worse pulmonary haemodynamics, and lower humoral regulators of ketogenesis (insulin/glucagon ratio). During a median follow-up of 1126 (IQR 410–1781) days, there were 512 composite events, including 324 deaths, 81 left ventricular assist device implantations and 107 urgent cardiac transplantations. In univariable Cox regression, increased β-OHB levels (T3 vs. T1: hazard ratio [HR] 1.39, 95% confidence interval [CI] 1.13–1.72, p = 0.002) and elevated FFA levels (T3 vs. T1: HR 1.39, 95% CI 1.09–1.79, p = 0.008) were both predictors of a worse prognosis. In multivariable Cox analysis evaluating the simultaneous associations of FFA and β-OHB levels with outcomes, only FFA levels remained significantly associated with adverse outcomes. Conclusions In patients with advanced HFrEF, increased plasma β-OHB correlate with FFA levels, worse right ventricular function, greater neurohormonal activation and other markers of HF severity. The association between plasma β-OHB and adverse outcomes is eliminated after accounting for FFA levels, suggesting that increased β-OHB is a consequence reflecting heightened lipolytic state, rather than a cause of worsening HF.
First Application of a Mixed Porcine–Human Repopulated Bioengineered Liver in a Preclinical Model of Post-Resection Liver Failure
Felgendreff, Philipp , Hosseiniasl, Seyed M. , Minshew, Anna, Amiot, Bruce , Wilken, Silvana, Ahmadzada, Boyukkhanim , Jalan‐Sakrikar, Nidhi , Engles, Noah G. , Halsten, Peggy, Mariakis, Kendra, Barry, John J., Riesgraf, Shawn A., Fecteau, Chris, Ross, Jeffrey , Nyberg, Scott L. , Hosseiniasl, Seyed Mohammad, Amiot, Bruce P, Sakrikar, Nidhi Jalan , Engles, Noah G , Nyberg, Scott L , Huebert, Robert C. , Barry, John, Ross, Jeffrey J.

Mayo Clinic

Biomedicines | June 7, 2024 | Volume: 12 | Issue: 6 | Pages: 1272

10.3390/biomedicines12061272 | PMID 38927479 Get It

In this study, a mixed porcine–human bioengineered liver (MPH-BEL) was used in a preclinical setup of extracorporeal liver support devices as a treatment for a model of post-resection liver failure (PRLF). The potential for human clinical application is further illustrated by comparing the functional capacity of MPH-BEL grafts as assessed using this porcine PRLF model with fully human (FH-BEL) grafts which were perfused and assessed in vitro. BEL grafts were produced by reseeding liver scaffolds with HUVEC and primary porcine hepatocytes (MPH-BEL) or primary human hepatocytes (FH-BEL). PRLF was induced by performing an 85% liver resection in domestic white pigs and randomized into the following three groups 24 h after resection: standard medical therapy (SMT) alone, SMT + extracorporeal circuit (ECC), and SMT + MPH-BEL. The detoxification and metabolic functions of the MPH-BEL grafts were compared to FH-BEL grafts which were perfused in vitro. During the 24 h treatment interval, INR values normalized within 18 h in the MPH-BEL therapy group and urea synthesis increased as compared to the SMT and SMT + ECC control groups. The MPH-BEL treatment was associated with more rapid decline in hematocrit and platelet count compared to both control groups. Histological analysis demonstrated platelet sequestration in the MPH-BEL grafts, possibly related to immune activation. Significantly higher rates of ammonia clearance and metabolic function were observed in the FH-BEL grafts perfused in vitro than in the MPH-BEL grafts. The MPH-BEL treatment was associated with improved markers of liver function in PRLF. Further improvement in liver function in the BEL grafts was observed by seeding the biomatrix with human hepatocytes. Methods to reduce platelet sequestration within BEL grafts is an area of ongoing research.
The NAVigate-HPV Registry: A comprehensive biomarker evidence base for HPV-driven cancers.
Kalman, Noah S. , Bhatia, Aarti , Jabalee, Jamie, Baliga, Sujith , Raben, Adam , Sims, John R. , Bhayani, Mihir K. , Roof, Scott , Hanna, Glenn J. , Rettig, Eleni M. , Routman, David M. , Holsinger, F. Christopher , Patel, Mihir R , Jabalee, Jamie, Yom, Sue S. , Sims, John, Kaczmar, John M. , Berger, Barry M. , Fitz, Catherine Del Vecchio

Mayo Clinic

Journal of Clinical Oncology | June 4, 2024 | Volume: 42 | Issue: 16_suppl | Pages: e15045-e15045

10.1200/jco.2024.42.16_suppl.e15045 Get It

e15045 Background: Human papillomavirus (HPV) is an oncogenic driver of several human cancers, including those of the anal canal, uterine cervix, and head and neck (predominantly oropharynx). Despite advancements in our understanding of HPV-related cancers, there remains an unmet need for a comprehensive biomarker-driven registry to establish correlations between biomarker detectability and clinicopathologic features in patients diagnosed and treated for HPV-driven cancers. To address this need, the NAVigate-HPV Registry has been established to systematically collect and analyze integrated biomarker and clinical data from many U.S. cancer centers. Methods: NavDx (Naveris, Inc.) is a clinically validated blood-based assay detecting circulating cell-free tumor tissue modified viral (TTMV)-HPV DNA. The NAVigate-HPV Registry is a web-based data platform based on a centrally IRB approved protocol. Participating investigators will include providers that order NavDx tests in the routine clinical care of their patients and agree to the terms and conditions for use of the registry. Eligible subjects will have or have had an HPV-driven cancer (with an initial focus on HPV-driven oropharynx cancer with confirmatory tissue testing) and have received one or more NavDx blood tests during routine clinical care. Clinical data and TTMV-HPV DNA scores will be collected at enrollment and defined intervals over five years or until death. Results: In the initial phase, the registry has enlisted participation and established a steering committee composed of a representative from each of 14 institutions. These institutions are geographically diverse centers ranging from community hospitals to clinics and academic medical facilities. An IRB protocol governing the registry will maintain ethical standards, ensuring compliance and ethical conduct throughout the registry process. Data extraction methods have been previously established to evaluate an initial cohort of 543 patients (Hanna GJ, Roof SA, et. al 2023). Conclusions: Naveris and collaborators have together successfully launched the NAVigate-HPV registry with the aim of creating a robust database linking tumor biomarker results from NavDx with clinical outcomes data for HPV-related cancers. The NAVigate-HPV database is expected to encompass more than 1,000 patients within 1 year and grow to > 5,000 patients within 5 years, serving as a powerful tool for precision cancer medicine in this patient cancer population. Establishing this registry will deepen insights into HPV-related cancers and advance diagnostic and therapeutic approaches to improve patient outcomes.
Pulmonary Hypertension Across the Spectrum of Left Heart and Lung Disease
Larive, Brett , Beck, Gerald J. , Erzurum, Serpil C. , Farha, Samar , Finet, J. Emanuel , Highland, Kristin B. , Jacob, Miriam , Jellis, Christine , Renapurkar, Rahul D., Singh, Harsimran , Vanderpool, Rebecca , Wilcox, Jennifer , Yu, Shilin , Hill, Nicholas S. , Vanderpool, Rebecca R , Wilcox, Jennifer D , Borlaug, Barry A. , Frantz, Robert P. , Hassoun, Paul M. , Hemnes, Anna R. , Horn, Evelyn M. , Leopold, Jane A. , Rischard, Franz , Rosenzweig, Erika B. , Mehra, Reena , Tang, W.H. Wilson

Mayo Clinic

European Journal of Heart Failure | June 4, 2024 | Volume: 26 | Issue: 7 | Pages: 1642-1651

10.1002/ejhf.3302 | PMID 38837273 Get It

Abstract Aims Patients with pulmonary hypertension (PH) are grouped based upon clinical and haemodynamic characteristics. Groups 2 (G2, left heart disease [LHD]) and 3 (G3, lung disease or hypoxaemia) are most common. Many patients display overlapping characteristics of heart and lung disease (G2–3), but this group is not well-characterized. Methods and results Patients with PH enrolled in the prospective, NHLBI-sponsored PVDOMICS network underwent intensive clinical, biomarker, imaging, gas exchange and exercise phenotyping. Patients with pure G2, pure G3, or overlapping G2–3 PH were compared across multiple phenotypic domains. Of all patients with predominant G2 (n = 136), 66 (49%) were deemed to have secondary lung disease/hypoxaemia contributors (G2/3), and of all patients categorized as predominant G3 (n = 172), 41 (24%) were judged to have a component of secondary LHD (G3/2), such that 107 had G2–3 (combined G2/3 and G3/2). As compared with G3, patients with G2 and G2–3 were more obese and had greater prevalence of hypertension, atrial fibrillation, and coronary disease. Patients with G2 and G2–3 were more anaemic, with poorer kidney function, more cardiac dysfunction, and higher N-terminal pro-B-type natriuretic peptide than G3. Lung diffusion was more impaired in G3 and G2–3, but commonly abnormal even in G2. Exercise capacity was severely and similarly impaired across all groups, with no differences in 6-min walk distance or peak oxygen consumption, and pulmonary vasoreactivity to nitric oxide did not differ. In a multivariable Cox regression model, patients with G2 had lower risk of death or transplant compared with G3 (hazard ratio [HR] 0.51, 95% confidence interval [CI] 0.30–0.86), and patients with G2–3 also displayed lower risk compared with G3 (HR 0.57, 95% CI 0.38–0.86). Conclusions Overlap is common in patients with a pulmonary or cardiac basis for PH. While lung structure/function is clearly more impaired in G3 and G2–3 than G2, pulmonary abnormalities are common in G2, even when clinically judged as isolated LHD. Further study is required to identify optimal systematic evaluations to guide therapeutic innovation for PH associated with combined heart and lung disease. Clinical Trial Registration: ClinicalTrials.gov NCT02980887.
Cardiac Function, Haemodynamics, and Valve Competence with Exercise in Patients with Heart Failure with Preserved Ejection Fraction and Mild to Moderate Secondary Mitral Regurgitation
Harada, Tomonari , Tada, Atsushi , Doi, Shunichi , Ibe, Tatsuro , Eleid, Mackram F. , Sorimachi, Hidemi, Reddy, Yogesh N.V. , Nishimura, Rick , Naser, Jwan A. , Doi, Shunichi, Pislaru, Sorin V. , Obokata, Masaru , Borlaug, Barry A.

Mayo Clinic

European Journal of Heart Failure | June 4, 2024 | Volume: 26 | Issue: 7 | Pages: 1616-1627

10.1002/ejhf.3322 | PMID 38837599 Get It

Abstract Aims This study aimed to evaluate the clinical significance of secondary mitral regurgitation (MR) in patients with heart failure with preserved ejection fraction (HFpEF). Methods and results We conducted a prospective study enrolling consecutively evaluated patients with HFpEF undergoing invasive haemodynamic exercise testing with simultaneous echocardiography. Compared to HFpEF without MR (n = 145, 79.7%), those with mild or moderate MR (n = 37, 20.3%) were older, more likely to be women, had more left ventricular (LV) systolic dysfunction, and more likely to have left atrial (LA) myopathy reflected by greater burden of atrial fibrillation, more LA dilatation, and poorer LA function. Pulmonary artery (PA) wedge pressure was higher at rest in HFpEF with MR (17 ± 5 mmHg vs. 20 ± 5 mmHg, p = 0.005), but there was no difference with exercise. At rest, only 2 (1.1%) patients had moderate MR, and none developed severe MR. Pulmonary vascular resistance was higher, and right ventricular (RV)-PA coupling was more impaired in patients with HFpEF and MR at rest and exercise. LV and LA myocardial dysfunction remained more severe in patients with MR during stress compared to those without MR, characterized by greater LA dilatation during all stages of exertion, lower LA emptying fraction and compliance, steeper and rightward-shifted LA pressure–volume relationships, and reduced LV longitudinal contractile function. Conclusions Patients with HFpEF and mild or moderate MR have more severe LV systolic dysfunction, LA myopathy, RV-PA uncoupling, and more severe pulmonary vascular disease. Mitral valve incompetence in this setting is a phenotypic marker of more advanced disease but is not a causal factor in development of HFpEF.
Two genome-wide interaction loci modify the association of nonsteroidal anti-inflammatory drugs with colorectal cancer
Drew, David A. , Kim, Andre E. , Lin, Yi , Morrison, John L. , Lewinger, Juan Pablo , Fu, Yubo, Zemlianskaia, Natalia , Díez‐Obrero, Virginia , Baurley, James W. , Wu, Anna H. , Prentice, Ross L. , Harlid, Sophia , Barry, Elizabeth L. , Berndt, Sonja I. , Bouras, Emmanouil , Burnett‐Hartman, Andrea N. , Casey, Graham , Chang‐Claude, Jenny , Figueiredo, Jane C. , Gruber, Stephen B. , Gsur, Andrea , Harrison, Tabitha A. , Huyghe, Jeroen R. , Jordahl, Kristina M. , Kundaje, Anshul , Li, Li , Newton, Christina C. , Obón‐Santacana, Mireia , Pai, Rish K. , Papadimitriou, Nikos , Scacheri, Peter C. , Schmit, Stephanie L. , Thomas, Duncan C. , Duijnhoven, Fränzel J.B. van , Guelpen, Bethany Van , Peters, Ulrike , Gauderman, W. James , Morrison, John L , Lewinger, Juan Pablo , Wang, Jun , Zemlianskaia, Natalia , Bien, Stephanie A , Dimou, Niki , Buchanan, Daniel D , Potter, John D , Prentice, Ross L , Harlid, Sophia , Arndt, Volker , Bouras, Emmanouil , Carreras-Torres, Robert , Casey, Graham , Devall, Matthew A M , Gruber, Stephen B , Gsur, Andrea , Gunter, Marc J , Harrison, Tabitha A , Hoffmeister, Michael , Huyghe, Jeroen R , Jenkins, Mark A , Jordahl, Kristina M , Kundaje, Anshul , Li, Li , Lynch, Brigid M , Nassir, Rami , Newton, Christina C , Ogino, Shuji , Ose, Jennifer , Pai, R K , Palmer, Julie R , Pardamean, Bens , Pellatt, Andrew J , Peoples, Anita R , Platz, Elizabeth A. , Rennert, Gad , Ruiz-Narvaez, Edward , Sakoda, Lori C , Schmit, Stephanie L , Schoen, Robert E , Su, Yu-Ru , Tian, Yu , Tsilidis, Konstantinos K , Ulrich, Cornelia M , Um, Caroline Y , van Duijnhoven, Fränzel J B , Van Guelpen, Bethany , Hsu, Li , Moreno, Victor , Peters, Ulrike , Chan, Andrew T , Gauderman, W James , Drew, David A , Obón-Santacana, Mireia , Papadimitriou, Nikos , Diez-Obrero, Virginia , Qu, Conghui , Kawaguchi, Eric , Bien, Stephanie A. , Dimou, Niki , Albanes, Demetrius , Buchanan, Daniel D. , Potter, John D. , Arndt, Volker , Brenner, Hermann , Budiarto, Arif , Campbell, Peter T. , Carreras‐Torres, Robert , Conti, David V. , Gunter, Marc J. , Hidaka, Akihisa , Hoffmeister, Michael , Jenkins, Mark A. , Marchand, Loı̈c Le , Murphy, Neil , Nassir, Rami , Newcomb, Polly A. , Ose, Jennifer , Palmer, Julie R. , Pardamean, Bens , Pellatt, Andrew J. , Rennert, Gad , Sakoda, Lori C. , Schoen, Robert E. , Stern, Mariana Carla , Tian, Yu , Tsilidis, Konstantinos K. , Ulrich, Cornelia M. , Um, Caroline Y. , White, Emily E. , Moreno, Vı́ctor , Chan, Andrew T.

Mayo Clinic

Science Advances | May 29, 2024 | Volume: 10 | Issue: 22 | Pages: No page available

10.1126/sciadv.adk3121 | PMID 38809988 Get It

Regular, long-term aspirin use may act synergistically with genetic variants, particularly those in mechanistically relevant pathways, to confer a protective effect on colorectal cancer (CRC) risk. We leveraged pooled data from 52 clinical trial, cohort, and case-control studies that included 30,806 CRC cases and 41,861 controls of European ancestry to conduct a genome-wide interaction scan between regular aspirin/nonsteroidal anti-inflammatory drug (NSAID) use and imputed genetic variants. After adjusting for multiple comparisons, we identified statistically significant interactions between regular aspirin/NSAID use and variants in 6q24.1 (top hit rs72833769 ), which has evidence of influencing expression of TBC1D7 (a subunit of the TSC1-TSC2 complex, a key regulator of MTOR activity), and variants in 5p13.1 (top hit rs350047 ), which is associated with expression of PTGER4 (codes a cell surface receptor directly involved in the mode of action of aspirin). Genetic variants with functional impact may modulate the chemopreventive effect of regular aspirin use, and our study identifies putative previously unidentified targets for additional mechanistic interrogation.
Digital dermatopathology implementation: Experience at a multisite academic institution
Proffer, Sydney L. , Reinhart, Jacob P. , Gerdes, Erin Wissler, Todd, Austin, Cervenka, Derek J., DiCaudo, David J. , Sokumbi, Olayemi , Johnson, Emma F. , Peters, Margot S. , Wieland, Carilyn N. , Comfere, Nneka I. , Gerdes, Erin O. Wissler , Reinhart, Jacob , Sokumbi, Olayemi , Comfere, Nneka , Larkin, Sydney C , Wissler Gerdes, Erin O , Ridgeway, Jennifer L. , Barry, Barbara , Kamath, Celia

Mayo Clinic

Journal of Cutaneous Pathology | May 24, 2024 | Volume: 51 | Issue: 9 | Pages: 696-704

10.1111/cup.14629 | PMID 38783791 Get It

AbstractBackgroundTechnology has revolutionized not only direct patient care but also diagnostic care processes. This study evaluates the transition from glass‐slide microscopy to digital pathology (DP) at a multisite academic institution, using mixed methods to understand user perceptions of digitization and key productivity metrics of practice change.MethodsParticipants included dermatopathologists, pathology reporting specialists, and clinicians. Electronic surveys and individual or group interviews included questions related to technology comfort, trust in DP, and rationale for DP adoption. Case volumes and turnaround times were abstracted from the electronic health record from Qtr 4 2020 to Qtr 1 2023 (inclusive). Data were analyzed descriptively, while interviews were analyzed using methods of content analysis.ResultsThirty‐four staff completed surveys and 22 participated in an interview. Case volumes and diagnostic turnaround time did not differ across the institution during or after implementation timelines (p = 0.084; p = 0.133, respectively). 82.5% (28/34) of staff agreed that DP improved the sign‐out experience, with accessibility, ergonomics, and annotation features described as key factors. Clinicians reported positive perspectives of DP impact on patient safety and interdisciplinary collaboration.ConclusionsOur study demonstrates that DP has a high acceptance rate, does not adversely impact productivity, and may improve patient safety and care collaboration.
Use of Federal Reimbursement for Living Donor Costs by Racial and Ethnic Minorities: Implications for Disparities in Access to Living Donor Transplantation
Mathur, Amit K. , Goodrich, Nathan P. , Mandell, Rebecca , Warren, Patricia H., Ojo, Akinlolu , Merion, Robert M. , Hong, Barry A. , Smith, Abigail R. , Gifford, Kimberly A.

Mayo Clinic

Transplantation | May 21, 2024 | Volume: 108 | Issue: 12 | Pages: 2409-2419

10.1097/tp.0000000000005013 | PMID 38771064 Get It

Background. Minority race, ethnicity, and financial barriers are associated with lower rates of living donor (LD) kidney transplantation (LDKT). Financial reimbursement for LD costs may impact social determinants of health and, therefore, impact disparities in access to LDKT. Methods. Among US LDKTs, we studied associations between racial and ethnic minority status and utilization of the National Living Donor Assistance Center (NLDAC), a means-tested reimbursement program for nonmedical LD costs. We analyzed demographic, clinical, income, and survey data from NLDAC and the Scientific Registry of Transplant Recipients (January 1, 2011, to December 31, 2022) to identify predictors of NLDAC utilization. Results. Among 70 069 US LDKTs, 6093 NLDAC applicants were identified (9% of US LDKTs). Racial and ethnic minorities were over-represented in NLDAC-supported LDKTs compared with non-NLDAC US LDKTs (Black donors 12% versus 9%; Black recipients 15% versus 12%; Hispanic donors 21% versus 14%; Hispanic recipients 23% versus 15%; all P < 0.001). Among preemptive transplants, use of NLDAC by donors to Hispanic recipients (11%) was nearly twice as high as that of non-Hispanic recipients (6%) (P < 0.001). At time of NLDAC application, 72% stated NLDAC “will make it possible” to donate; higher proportions of minority applicants agreed (Black 80%, White 70%, P < 0.001; Hispanic 79%, non-Hispanic 70%, P < 0.001). Racial and ethnic minority-concordant transplants were significantly more likely to use NLDAC (donor/recipient: Black/Black risk-adjusted odds ratio [OR], 1.85, other/other OR 2.59, Hispanic/Hispanic OR 1.53; all P < 0.05). Conclusions. Reduction of LD financial barriers may increase access to LDKT, particularly in racial and ethnic minority communities.
The Spike Protein of the Causative COVID-19 Virus Induces Heme Oxygenase-1: Pathophysiologic Implications
Singh, Raman D., Barry, Maureen, Croatt, Anthony J., Ackerman, Allan W., Grande, Joseph P. , Agarwal, Anupam, Nath, Karl A. , Singh, Raman D., Ackerman, Allan W., Agarwal, Anupam

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 32 | Issue: 10S | Pages: 39-39

10.1681/asn.20213210s139b Get It